338 related articles for article (PubMed ID: 25418333)
1. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.
Zeglis BM; Davis CB; Abdel-Atti D; Carlin SD; Chen A; Aggeler R; Agnew BJ; Lewis JS
Bioconjug Chem; 2014 Dec; 25(12):2123-8. PubMed ID: 25418333
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
3. Site-Specific Photoaffinity Bioconjugation for the Creation of
Delaney S; Nagy Á; Karlström AE; Zeglis BM
Mol Imaging Biol; 2023 Dec; 25(6):1104-1114. PubMed ID: 37052759
[TBL] [Abstract][Full Text] [Related]
4. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
[TBL] [Abstract][Full Text] [Related]
5. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.
Cook BE; Adumeau P; Membreno R; Carnazza KE; Brand C; Reiner T; Agnew BJ; Lewis JS; Zeglis BM
Bioconjug Chem; 2016 Aug; 27(8):1789-95. PubMed ID: 27356886
[TBL] [Abstract][Full Text] [Related]
6. A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer.
Adumeau P; Carnazza KE; Brand C; Carlin SD; Reiner T; Agnew BJ; Lewis JS; Zeglis BM
Theranostics; 2016; 6(12):2267-2277. PubMed ID: 27924162
[TBL] [Abstract][Full Text] [Related]
7. Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET.
Adumeau P; Vivier D; Sharma SK; Wang J; Zhang T; Chen A; Agnew BJ; Zeglis BM
Mol Pharm; 2018 Mar; 15(3):892-898. PubMed ID: 29356543
[TBL] [Abstract][Full Text] [Related]
8. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
9. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
10. Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.
Zeglis BM; Brand C; Abdel-Atti D; Carnazza KE; Cook BE; Carlin S; Reiner T; Lewis JS
Mol Pharm; 2015 Oct; 12(10):3575-87. PubMed ID: 26287993
[TBL] [Abstract][Full Text] [Related]
11. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
12. Site-Specific, Platform-Based Conjugation Strategy for the Synthesis of Dual-Labeled Immunoconjugates for Bimodal PET/NIRF Imaging of HER2-Positive Tumors.
Adumeau P; Raavé R; Boswinkel M; Heskamp S; Wessels HJCT; van Gool AJ; Moreau M; Bernhard C; Da Costa L; Goncalves V; Denat F
Bioconjug Chem; 2022 Mar; 33(3):530-540. PubMed ID: 35230093
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.
Zeglis BM; Davis CB; Aggeler R; Kang HC; Chen A; Agnew BJ; Lewis JS
Bioconjug Chem; 2013 Jun; 24(6):1057-67. PubMed ID: 23688208
[TBL] [Abstract][Full Text] [Related]
14.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Evaluation of Antibody Modification and
Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
[TBL] [Abstract][Full Text] [Related]
16. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.
Zeglis BM; Sevak KK; Reiner T; Mohindra P; Carlin SD; Zanzonico P; Weissleder R; Lewis JS
J Nucl Med; 2013 Aug; 54(8):1389-96. PubMed ID: 23708196
[TBL] [Abstract][Full Text] [Related]
17. Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies.
Meimetis LG; Boros E; Carlson JC; Ran C; Caravan P; Weissleder R
Bioconjug Chem; 2016 Jan; 27(1):257-63. PubMed ID: 26684717
[TBL] [Abstract][Full Text] [Related]
18. Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans.
Adumeau P; Sharma SK; Brent C; Zeglis BM
Mol Imaging Biol; 2016 Feb; 18(1):1-17. PubMed ID: 26754790
[TBL] [Abstract][Full Text] [Related]
19. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.
Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ
Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250
[TBL] [Abstract][Full Text] [Related]
20.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
